Systematic therapeutic drug monitoring for linezolid: Variability and clinical impact

Alicia Galar; Maricela Valerio; Patricia Muñoz; Luis Alcalá; Xandra García-González; Almudena Burillo; María Sanjurjo; Santiago Grau; Emilio Bouza

doi:10.1128/AAC.00687-17

Systematic therapeutic drug monitoring for linezolid: Variability and clinical impact

Alicia Galar, Maricela Valerio, Patricia Muñoz, Luis Alcalá, Xandra García-González, Almudena Burillo, María Sanjurjo, Santiago Grau, Emilio Bouza

Department of Pharmacology, Therapeutics and Toxicology

Research output: Contribution to journal › Article › Research › peer-review

9 Citations (Scopus)

Abstract

© 2017 American Society for Microbiology. All Rights Reserved. Linezolid serum trough (Cmin) and peak (Cmax) levels were determined prospectively in 90 patients. Adequate exposure was defined as a Cmin of 2 to 8 mg/liter. Therapy was empirical (73.3%) or targeted (26.7%). Wide interindividual variability in linezolid Cmin levels was recorded (0.1 to 25.2 μg/ml). Overall, 65.5% of the patients had out-of-range, 41.1% had subtherapeutic, and 24.4% had supratherapeutic trough levels. We did not find a correlation between abnormal levels and adverse events, in-hospital mortality, or overall poor outcome.

Original language	English
Journal	Antimicrobial Agents and Chemotherapy
Volume	61
Issue number	10
DOIs	https://doi.org/10.1128/AAC.00687-17
Publication status	Published - 1 Jan 2017

Keywords

Drugs for Gram-positive bacteria
Linezolid
Therapeutic drug monitoring

Access to Document

10.1128/AAC.00687-17

Fingerprint Dive into the research topics of 'Systematic therapeutic drug monitoring for linezolid: Variability and clinical impact'. Together they form a unique fingerprint.

Cite this

@article{cde8e0526325455286e747d85ac8f1f2,

title = "Systematic therapeutic drug monitoring for linezolid: Variability and clinical impact",

abstract = "{\textcopyright} 2017 American Society for Microbiology. All Rights Reserved. Linezolid serum trough (Cmin) and peak (Cmax) levels were determined prospectively in 90 patients. Adequate exposure was defined as a Cmin of 2 to 8 mg/liter. Therapy was empirical (73.3%) or targeted (26.7%). Wide interindividual variability in linezolid Cmin levels was recorded (0.1 to 25.2 μg/ml). Overall, 65.5% of the patients had out-of-range, 41.1% had subtherapeutic, and 24.4% had supratherapeutic trough levels. We did not find a correlation between abnormal levels and adverse events, in-hospital mortality, or overall poor outcome.",

keywords = "Drugs for Gram-positive bacteria, Linezolid, Therapeutic drug monitoring",

author = "Alicia Galar and Maricela Valerio and Patricia Mu{\~n}oz and Luis Alcal{\'a} and Xandra Garc{\'i}a-Gonz{\'a}lez and Almudena Burillo and Mar{\'i}a Sanjurjo and Santiago Grau and Emilio Bouza",

year = "2017",

month = jan,

day = "1",

doi = "10.1128/AAC.00687-17",

language = "English",

volume = "61",

number = "10",

}

Systematic therapeutic drug monitoring for linezolid: Variability and clinical impact. / Galar, Alicia; Valerio, Maricela; Muñoz, Patricia; Alcalá, Luis; García-González, Xandra; Burillo, Almudena; Sanjurjo, María; Grau, Santiago; Bouza, Emilio.

In: Antimicrobial Agents and Chemotherapy, Vol. 61, No. 10, 01.01.2017.

Research output: Contribution to journal › Article › Research › peer-review

TY - JOUR

T1 - Systematic therapeutic drug monitoring for linezolid: Variability and clinical impact

AU - Galar, Alicia

AU - Valerio, Maricela

AU - Muñoz, Patricia

AU - Alcalá, Luis

AU - García-González, Xandra

AU - Burillo, Almudena

AU - Sanjurjo, María

AU - Grau, Santiago

AU - Bouza, Emilio

PY - 2017/1/1

Y1 - 2017/1/1

N2 - © 2017 American Society for Microbiology. All Rights Reserved. Linezolid serum trough (Cmin) and peak (Cmax) levels were determined prospectively in 90 patients. Adequate exposure was defined as a Cmin of 2 to 8 mg/liter. Therapy was empirical (73.3%) or targeted (26.7%). Wide interindividual variability in linezolid Cmin levels was recorded (0.1 to 25.2 μg/ml). Overall, 65.5% of the patients had out-of-range, 41.1% had subtherapeutic, and 24.4% had supratherapeutic trough levels. We did not find a correlation between abnormal levels and adverse events, in-hospital mortality, or overall poor outcome.

AB - © 2017 American Society for Microbiology. All Rights Reserved. Linezolid serum trough (Cmin) and peak (Cmax) levels were determined prospectively in 90 patients. Adequate exposure was defined as a Cmin of 2 to 8 mg/liter. Therapy was empirical (73.3%) or targeted (26.7%). Wide interindividual variability in linezolid Cmin levels was recorded (0.1 to 25.2 μg/ml). Overall, 65.5% of the patients had out-of-range, 41.1% had subtherapeutic, and 24.4% had supratherapeutic trough levels. We did not find a correlation between abnormal levels and adverse events, in-hospital mortality, or overall poor outcome.

KW - Drugs for Gram-positive bacteria

KW - Linezolid

KW - Therapeutic drug monitoring

U2 - 10.1128/AAC.00687-17

DO - 10.1128/AAC.00687-17

M3 - Article

VL - 61

IS - 10

ER -